Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Upgraded to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) from a hold rating to a strong-buy rating in a research note published on Thursday,Zacks reports.

Separately, Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. Three research analysts have rated the stock with a Strong Buy rating. According to data from MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR currently has an average rating of “Strong Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Up 1.0%

SGIOY traded up $0.09 during trading on Thursday, hitting $9.22. 163,940 shares of the stock were exchanged, compared to its average volume of 95,038. Shionogi & Co., Ltd. Unsponsored ADR has a 1 year low of $7.83 and a 1 year high of $12.00. The firm has a market cap of $15.69 billion, a price-to-earnings ratio of 9.22, a P/E/G ratio of 3.27 and a beta of 0.08. The firm has a 50 day simple moving average of $9.07 and a 200 day simple moving average of $9.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.00 and a current ratio of 1.14.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.18. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. As a group, equities analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.